Abstract
Programmed cell death 1 (PD-1) inhibitors used as target anti-cancer immunotherapy have been largely reported for their cutaneous immune-related adverse events (irAEs) ranging from xeroderma or pruritus to atopic dermatitis, psoriasis, vitiligo, etc. Autoimmune blistering diseases (AIBD) from the pemphigoid spectrum, namely bullous pemphigoid (BP) and rarely lichen planus pemphigoides (LPP) have also been associated with checkpoint inhibitors (CI). There is a growing interest in investigating their causal relation, characteristics, and treatment response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
